Announced
Completed
Financials
Tags
biotechnology
Biotechnology
Private
Minority
Single Bidder
drug discovery
developing therapies
Acquisition
Cross Border
United States
Completed
Friendly
Synopsis
Sanofi, a global healthcare company, completed the investment in Graviton Bioscience, a clinical-stage drug discovery and development firm. Financial terms were not disclosed. "This investment in Graviton Bioscience reflects our commitment to innovative therapies and providing patients with novel medicines and vaccines. Graviton's scientific expertise in discovering and developing the next wave of innovation has the potential to significantly enhance the landscape of therapeutic possibilities," Paul Hudson, Sanofi CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.